Canada - English - Health Canada

grifols therapeutics llc - immunoglobulin (human) - solution - 10g - immunoglobulin (human) 10g - serums

United States - English - NLM (National Library of Medicine)

northstar rxllc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone tablets are indicated for treatment of nyha class iii–iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 500 mg

United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 500 mg

United States - English - NLM (National Library of Medicine)

quality care products, llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

county line pharmaceuticals, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets is indicated for the prevention of - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets are also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular achycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, its use shou

United States - English - NLM (National Library of Medicine)

greenstone llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated for treatment of nyha class iii–iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone is usually administered in conjunction with other heart failure therapies. spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure

United States - English - NLM (National Library of Medicine)

northstar rx llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

northstar rx llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru